Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

61 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis.
WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group; Shankar-Hari M, Vale CL, Godolphin PJ, Fisher D, Higgins JPT, Spiga F, Savovic J, Tierney J, Baron G, Benbenishty JS, Berry LR, Broman N, Cavalcanti AB, Colman R, De Buyser SL, Derde LPG, Domingo P, Omar SF, Fernandez-Cruz A, Feuth T, Garcia F, Garcia-Vicuna R, Gonzalez-Alvaro I, Gordon AC, Haynes R, Hermine O, Horby PW, Horick NK, Kumar K, Lambrecht BN, Landray MJ, Leal L, Lederer DJ, Lorenzi E, Mariette X, Merchante N, Misnan NA, Mohan SV, Nivens MC, Oksi J, Perez-Molina JA, Pizov R, Porcher R, Postma S, Rajasuriar R, Ramanan AV, Ravaud P, Reid PD, Rutgers A, Sancho-Lopez A, Seto TB, Sivapalasingam S, Soin AS, Staplin N, Stone JH, Strohbehn GW, Sunden-Cullberg J, Torre-Cisneros J, Tsai LW, van Hoogstraten H, van Meerten T, Veiga VC, Westerweel PE, Murthy S, Diaz JV, Marshall JC, Sterne JAC. WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, et al. Among authors: strohbehn gw. JAMA. 2021 Aug 10;326(6):499-518. doi: 10.1001/jama.2021.11330. JAMA. 2021. PMID: 34228774 Free PMC article.
Interventional Pharmacoeconomics: A Novel Mechanism for Unlocking Value.
Serritella AV, Strohbehn GW, Goldstein DA, Lichter AS, Ratain MJ. Serritella AV, et al. Among authors: strohbehn gw. Clin Pharmacol Ther. 2020 Sep;108(3):487-493. doi: 10.1002/cpt.1853. Epub 2020 May 12. Clin Pharmacol Ther. 2020. PMID: 32298471 Review.
Interventional Pharmacoeconomics.
Goldstein DA, Strohbehn GW, Serritella AV, Hyman DA, Lichter AS, Ratain MJ. Goldstein DA, et al. Among authors: strohbehn gw. Cancer J. 2020 Jul-Aug;26(4):330-334. doi: 10.1097/PPO.0000000000000461. Cancer J. 2020. PMID: 32732676 Review.
COVIDOSE: Low-dose tocilizumab in the treatment of Covid-19.
Strohbehn GW, Heiss BL, Rouhani SJ, Trujillo JA, Yu J, Kacew AJ, Higgs EF, Bloodworth JC, Cabanov A, Wright RC, Koziol A, Weiss A, Danahey K, Karrison TG, Edens CC, Ventura IB, Pettit NN, Patel B, Pisano J, Strek ME, Gajewski TF, Ratain MJ, Reid PD. Strohbehn GW, et al. medRxiv [Preprint]. 2020 Jul 26:2020.07.20.20157503. doi: 10.1101/2020.07.20.20157503. medRxiv. 2020. PMID: 32743594 Free PMC article. Updated. Preprint.
COVIDOSE: A Phase II Clinical Trial of Low-Dose Tocilizumab in the Treatment of Noncritical COVID-19 Pneumonia.
Strohbehn GW, Heiss BL, Rouhani SJ, Trujillo JA, Yu J, Kacew AJ, Higgs EF, Bloodworth JC, Cabanov A, Wright RC, Koziol AK, Weiss A, Danahey K, Karrison TG, Edens CC, Bauer Ventura I, Pettit NN, Patel BK, Pisano J, Strek ME, Gajewski TF, Ratain MJ, Reid PD. Strohbehn GW, et al. Clin Pharmacol Ther. 2021 Mar;109(3):688-696. doi: 10.1002/cpt.2117. Epub 2020 Dec 10. Clin Pharmacol Ther. 2021. PMID: 33210302 Free PMC article. Clinical Trial.
Socially optimal pandemic drug dosing.
Strohbehn GW, Parker WF, Reid PD, Gellad WF. Strohbehn GW, et al. Lancet Glob Health. 2021 Aug;9(8):e1049-e1050. doi: 10.1016/S2214-109X(21)00251-5. Epub 2021 Jun 14. Lancet Glob Health. 2021. PMID: 34139194 Free PMC article. No abstract available.
Combination therapy patents: a new front in evergreening.
Strohbehn GW, Kacew AJ, Goldstein DA, Feldman RC, Ratain MJ. Strohbehn GW, et al. Nat Biotechnol. 2021 Dec;39(12):1504-1510. doi: 10.1038/s41587-021-01137-6. Nat Biotechnol. 2021. PMID: 34880460 No abstract available.
Lorlatinib Exposed: A Far From Optimal Dose.
Strohbehn GW, Ratain MJ. Strohbehn GW, et al. Clin Pharmacol Ther. 2022 Jun;111(6):1195-1196. doi: 10.1002/cpt.2579. Epub 2022 Apr 8. Clin Pharmacol Ther. 2022. PMID: 35394660 No abstract available.
61 results